Abstract:Pulmonary fibrosis (PF) is a severe pulmonary disease with limited available therapeutic choices. Recent evidence increasingly points to abnormal lipid metabolism as a critical factor in PF pathogenesis. Our latest research identifies the dysregulation of low-density lipoprotein (LDL) is a new risk factor for PF, contributing to alveolar epithelial and endothelial cell damage, and fibroblast activation. In this study, we first integrative summarize the published literature about lipid metabolite changes found in PF, including phospholipids, glycolipids, steroids, fatty acids, triglycerides, and lipoproteins. We then reanalyze two single-cell RNA-sequencing (scRNA-seq) datasets of PF, and the corresponding lipid metabolomic genes responsible for these lipids' biosynthesis, catabolism, transport, and modification processes are uncovered. Intriguingly, we found that macrophage is the most active cell type in lipid metabolism, with almost all lipid metabolic genes being altered in macrophages of PF. In type 2 alveolar epithelial cells, lipid metabolic differentially expressed genes (DEGs) are primarily associated with the cytidine diphosphate diacylglycerol pathway, cholesterol metabolism, and triglyceride synthesis. Endothelial cells are partly responsible for sphingomyelin, phosphatidylcholine, and phosphatidylethanolamines reprogramming as their metabolic genes are dysregulated in PF. Fibroblasts may contribute to abnormal cholesterol, phosphatidylcholine, and phosphatidylethanolamine metabolism in PF. Therefore, the reprogrammed lipid profiles in PF may be attributed to the aberrant expression of lipid metabolic genes in different cell types. Taken together, these insights underscore the potential of targeting lipid metabolism in developing innovative therapeutic strategies, potentially leading to extended overall survival in individuals affected by PF.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the specific mechanism of abnormal lipid metabolism in pulmonary fibrosis (PF) and its role in disease progression. Specifically, the article mainly focuses on the following aspects: 1. **Summarize the known changes in lipid metabolites in PF**: including phospholipids, glycolipids, steroids, fatty acids, triglycerides and lipoproteins, etc., and explore the relationship between these changes and the pathological process of PF. 2. **Re - analyze single - cell RNA sequencing (scRNA - seq) data sets**: By analyzing two publicly available scRNA - seq data sets, reveal the expression changes of lipid - metabolism - related genes in different cell types, especially those genes involved in lipid biosynthesis, degradation, transport and modification processes. 3. **Explore the important role of macrophages in lipid metabolism**: It is found that macrophages are the most active lipid - metabolism cell type, and almost all lipid - metabolism genes are altered in macrophages of PF patients. 4. **Study the differences in lipid metabolism in different types of cells**: - **Type II alveolar epithelial cells (AT2 cells)**: Mainly involve the cytidine diphosphate diacylglycerol (CDP - diacylglycerol) pathway, cholesterol metabolism and triglyceride synthesis. - **Endothelial cells**: Are partly responsible for the reprogramming of sphingomyelin, phosphatidylcholine and phosphatidylethanolamine, because these metabolic genes are dysregulated in PF. - **Fibroblasts**: May be involved in abnormal cholesterol, phosphatidylcholine and phosphatidylethanolamine metabolism. 5. **Propose the possibility of lipid metabolism as a potential therapeutic target**: Based on the above research results, the authors believe that interventions targeting lipid metabolism may provide new directions for the development of innovative PF treatment strategies, thereby prolonging the survival of affected individuals. ### Formulas and Mechanisms - **Phospholipid Metabolism Pathway**: - Kennedy Pathway: \[ \text{PC} = \text{CTP} + \text{CDP - choline} + \text{DAG} \xrightarrow{\text{CHPT1}} \text{PC} \] \[ \text{PE} = \text{ETNK1/2} + \text{PCYT2} + \text{CEPT1} \] - **Sphingomyelin Metabolism Pathway**: \[ \text{SM} \xrightarrow{\text{SGMS1}} \text{Ceramide} \xrightarrow{\text{SMPD1 - 4}} \text{Sphingosine} \xrightarrow{\text{SPHK1}} \text{S1P} \] - **Cholesterol Metabolism**: \[ \text{Cholesterol} \xrightarrow{\text{TGF - β/NF - κB}} \text{ECM Deposition} \] \[ \text{25 - hydroxycholesterol} \xrightarrow{\text{TGF - β/NF - κB}} \text{Myofibroblast Differentiation} \] ### Conclusion Through in - depth research on lipid metabolism, the authors revealed the patterns of lipid - metabolism disorders in different cell types in PF and proposed that treatment strategies targeting lipid metabolism may help improve the prognosis of PF patients.

The novel molecular mechanism of pulmonary fibrosis: insight into lipid metabolism from reanalysis of single-cell RNA-seq databases

Reexamining the Role of Pulmonary Lipids in the Pathogenesis of Pulmonary Fibrosis

Integrated analysis of single-cell and bulk RNA sequencing reveals pro-fibrotic PLA2G7high macrophages in pulmonary fibrosis

Metabolic reprogramming of pulmonary fibrosis

Lipid metabolism in idiopathic pulmonary fibrosis: From pathogenesis to therapy

Cellular and Molecular Control of Lipid Metabolism in Idiopathic Pulmonary Fibrosis: Clinical Application of the Lysophosphatidic Acid Pathway

LDLR dysfunction induces LDL accumulation and promotes pulmonary fibrosis

Pulmonary fibrosis: pathogenesis and therapeutic strategies

High-Fat Diet Related Lung Fibrosis-Epigenetic Regulation Matters

Epigenetic hallmarks in pulmonary fibrosis: New advances and perspectives

Decoding the role of fatty acids and their metabolites in lung fibrosis

Immune cells crosstalk Pathways, and metabolic alterations in Idiopathic pulmonary fibrosis

Complex Involvement of the Extracellular Matrix, Immune Effect, and Lipid Metabolism in the Development of Idiopathic Pulmonary Fibrosis

Disturbance of serum lipid metabolites and potential biomarkers in the Bleomycin model of pulmonary fibrosis in young mice

Dynamic atlas of immune cells reveals multiple functional features of macrophages associated with progression of pulmonary fibrosis

Glycolysis and beyond in glucose metabolism: exploring pulmonary fibrosis at the metabolic crossroads

Comprehensive analysis of single-cell transcriptomics and genetic factors reveals the mechanisms and preventive strategies for the progression from pulmonary fibrosis to lung cancer

Regulating the cell shift of endothelial cell-like myofibroblasts in pulmonary fibrosis

Therapeutic effects of fatty acid binding protein 1 in mice with pulmonary fibrosis by regulating alveolar epithelial regeneration

Integrated multiomic analysis identifies as a mediator of alveolar epithelial type II cell dysfunction in idiopathic pulmonary fibrosis

Pharmaceutical targeting of succinate dehydrogenase in fibroblasts controls bleomycin-induced lung fibrosis